Evidence map›Paper›PMID 40552140›Full record

ArticleBlood neoplasia2024

Targeting SLFN11-regulated pathways restores chemotherapy sensitivity in AML.

Sara H Small, Ricardo E Perez, Elspeth M Beauchamp, Aneta H Baran, Stephen D Willis, Mariafausta Fischietti, Michael Schieber, Masha Kocherginsky, Diana Saleiro, Leonidas C Platanias

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sara H SmallRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.
Ricardo E PerezRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.
Elspeth M BeauchampRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.
Aneta H BaranRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.
Stephen D WillisNuclear Dynamics and Cancer Program, Fox Chase Cancer Center, Philadelphia, PA.
Mariafausta FischiettiRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.
Michael SchieberRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.
Masha KocherginskyRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.
Diana SaleiroRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.
Leonidas C PlataniasRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.

Funding

Signal Transduction of Type I Interferons in Malignant CellsR01CA077816 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PLATANIAS, LEONIDAS C. · 1998 to 2024
$6.6M
Targeting Novel Protein Complexes for the Treatment of Acute Myeloid LeukemiaR01CA121192 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI PLATANIAS, LEONIDAS C. · 2006 to 2023
$4.1M
CSRD VA I01 CX000916NCI NIH HHS R01 CA077816NCI NIH HHS R01 CA121192
6 · The paper itself

Abstract

Chemoresistance represents an ongoing challenge in treating patients with acute myeloid leukemia (AML), and a better understanding of the resistance mechanisms can lead to the development of novel AML therapies. Here, we demonstrated that low expression of the DNA damage response gene Schlafen 11 (

Identifiers

PMID40552140
PMCPMC12182837

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.